Phase I – First Administration to Humans

783 trials 323 recruiting

Filter these 783 trials by condition, country, sponsor and more.

Open in Search →

Phase I study of IAG933 in patients with advanced Mesothelioma and other solid tumors Ended

2023-508369-34-00 Advanced mesothelioma or other solid tumors harboring c 2021-12-07
A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combina… Ended

2023-510307-22-00 Advanced head and neck cancer 2021-09-24
A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer Ended

2023-506585-31-00 Metastatic castration-resistant prostate cancer 2021-07-09
A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination with other Anti-Cancer Therap… Ended

2023-506311-18-00 Advanced or metastatic solid tumors with KRAS G12C muta 2021-06-29
Study of BGB-11417 in Patients with Mature B Cell Malignancies Ended

2024-515592-35-00 Mature B Cell Malignancies 2021-06-14
Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations. Ended

2024-515149-41-00 Advanced Hematologic Malignancies 2021-02-04
A Phase 1 Study on the effects of LY3410738 (study drug) administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 Mutations Ended

2024-515150-24-00 Patients with IDH1 R132, IDH2 R140 or IDH2 R172-mutant 2021-01-19
First-in-human Study to Test Safety and Anti-tumor Activity of a Novel Drug for Patients with Advanced Solid Tumor Harboring Genetic Alterat… Ended

2023-510450-16-00 Phase 1: Advanced solid tumors harboring genetic altera 2020-12-16
Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Sub… Ended

2023-508281-15-00 Locally Advanced or Metastatic Solid Tumors 2020-11-10
This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in c… Ended

2023-504491-15-00 Human epidermal growth factor receptor (HER2)-Expressin 2020-10-30
A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites Ended

2022-500660-35-00 Allergy to House Dust Mites 2020-02-17
Dose Escalation and Dose Expansion Study of PD1-LAG3 Bispecific Antibody in Patients with Advanced and/or Metastatic Solid Tumors Ended

2023-503425-18-00 Metastatic Solid Tumors 2019-10-02
A Study to Evaluate MEDI5752 in Subjects with Advanced Solid Tumors Ended

2023-509605-77-00 Advanced solid tumours 2019-06-27
Study of TSR-022, a Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended

2023-507564-39-00 Patients with Advanced Solid Tumors 2019-03-11
Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer Ended

2023-506890-37-00 "Estrogen Receptor Positive HER2 Negative Advanced Brea 2019-03-01
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Amivantamab (JNJ61186372), a Human Bispecific EGFR and cMet Antibody, in Par… Ended

2023-509435-11-00 Advanced Non-Small Cell Lung Cancer 2019-02-21
A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300… Ended

2023-506541-39-00 Small Cell Lung Cancer 2018-08-03
MB-CART19.1 r/r CD19+ BCM Ended

2024-513334-38-00 Refractory/relapsed B-NHL 2018-05-15
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended

2023-506390-35-00 Patients with Advanced Solid Tumors 2017-04-19
A Study of LY3200882 in Participants With Solid Tumors. Ended

2023-507177-17-00 Metastatic cancer 2016-11-21
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations Ended

2023-507421-41-00 Advanced malignancies that harbor IDH1R132 mutations 2015-07-20
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors Halted

2024-512927-36-00 Advanced or Metastatic Urothelial Carcinoma or Other So 2025-10-30
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of T7-010 in Healthy Participants. Halted

2024-518440-20-00 Autoimmune Diseases (Healthy Volunteers) 2025-09-16
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors with KRAS G12D Mutation Halted

2023-507091-47-00 Advanced or metastatic solid tumors 2025-02-10